Guidance
← 실적 발표
01
02
03
04 05 06
톤
자본지출
A1 A2 A3 A4
CTVA
FY2026 Q2
개선
Corteva, Inc. 실적 발표
Buzzberg 분석
Full-year guidance raised with EBITDA and EPS increases.
Corteva beat expectations in Q2 and raised full-year 2026 guidance on strong execution in seed and crop protection. The company is on track to complete its separation on October 1st, with management outlining a clear path to meeting long-term targets. Key drivers are technology adoption, licensing growth, and cost/productivity improvements, offset by competitive pricing pockets in Brazil. Raised 2026 guidance: EBITDA to $4.1-4.3B, EPS to $3.60-3.80, margin to 22.5-23.5%.
Buzzberg 분석 Full-year guidance raised with EBITDA and EPS increases. Corteva beat expectations in Q2 and raised full-year 2026 guidance on strong execution in seed and crop protection. The company is on track to complete its separation on October 1st, with management outlining a clear path to meeting long-term targets. Key drivers are technology adoption, licensing growth, and cost/productivity improvements, offset by competitive pricing pockets in Brazil. Raised 2026 guidance: EBITDA to $4.1-4.3B, EPS to $3.60-3.80, margin to 22.5-23.5%. 전체 분석 보기분석 접기
Corteva beat expectations in Q2 and raised full-year 2026 guidance on strong execution in seed and crop protection. The company is on track to complete its separation on October 1st, with management outlining a clear path to meeting long-term targets. Key drivers are technology adoption, licensing growth, and cost/productivity improvements, offset by competitive pricing pockets in Brazil. Raised 2026 guidance: EBITDA to $4.1-4.3B, EPS to $3.60-3.80, margin to 22.5-23.5%.
- H1 2026: Sales up 4% to $11.3B, EBITDA up 10% to $3.7B, margin up 190bps to 32.8%.
- Separation (Vylor) on track for Oct 1, with net synergies impact largely offset to a ~$25M headwind for 2026.
- Crop protection new product portfolio on track to reach $2B revenue this year, offsetting price declines in generics.
매출$6.379B+30% 전분기 대비
주당순이익(EPS)$2.30+53% 전분기 대비
매출총이익률54.35%보고값
영업이익률30.02%보고값
근거 있는 핵심 내용 6개
지금 중요한 점
이번 발표에서 가장 의미 있는 변화를 정리했습니다.
Separation
Separation on track for October 1 with minimal dis-synergies.
Crop Protection
Crop protection new products approaching $2 billion revenue.
핵심 내용 3개 더 보기
Seed
Seed licensing business three years ahead of plan.
Pricing
Brazil crop protection pricing remains under pressure.
Demand
Brazilian farmer credit tightness noted as a watch item.
보고 기간
보고 실적
| 지표 | 보고값 | 변화 |
|---|---|---|
| 매출 | $6.379B | +30% 전분기 대비 |
| 주당순이익(EPS) | $2.30 | +53% 전분기 대비 |
| 매출총이익률 | 54.35% | 보고값 |
| 영업이익률 | 30.02% | 보고값 |
| 잉여현금흐름 | $-3.56B | -20% 전분기 대비 |
| 자본지출 | $0.203B | 보고값 |
향후 전망
향후 가이던스
| 지표 | 기간 | 범위 | 중간값 | 상태 |
|---|---|---|---|---|
| 주당순이익(EPS) | FY2026 | $3.60–$3.80 | $3.70 | 상향 |
| 영업이익률 | FY2026 | 22.5%–23.5%컨센서스 부합 | 23% | 상향 |
| 영업이익률 | FY2026 | $4.1B–$4.3B | $4.2B | 상향 |
AI, 자본지출 및 수요 분석
경영진 분석
Confident
Management expressed confidence in raising full-year guidance, highlighted strong execution, and emphasized on-track separation progress, all conveying a positive outlook.
투자 및 생산능력
Management discussed productivity improvements, cost management, and asset optimization, but no specific forward-looking capex figures were provided.
외부 신호
공급망 알파 · 4발표 이후 수익률
Corteva's licensing business is running three years ahead of plan, contributing to the 'net royalty positive' position for the first time.
근거
“licensing is literally three years ahead of our original plan, which is pretty astonishing considering that is a brand new business for us.”
Corteva anticipates a Q3 operating EBITDA loss of ~$100M, more typical of past years, with H2 EBITDA expected to be flat at ~$500M.
근거
“if you recall, our second half in 2025 was up 16% versus 2024. So we are comparing against a pretty strong half at about $500 million. ... Our second half is about 12% of our full year guide. And that's very much in line with the past four…”
Management states that the China-to-Brazil export market is stable, and the channel is not oversupplied, ready for the next season. This suggests the prior high-import inventory deluge is over.
근거
“when you look at Chinese exports into Brazil, they're essentially stable. They're not going down, but they're certainly not going up.”
Corteva is seeing competitive tension and price declines on off-patent molecules (e.g., pre-emergent herbicides in Brazil), but it has pre-emptively lowered its cost base on these products, allowing it to maintain margins and share.
근거
“We were really anticipating that we were going to see generic pressure. And we went really to work on our cost structure. And what we found is that we had to, of course, lower our prices because there's generics in the marketplace. But if…”
방법론 및 범위
경영진 발언만 분석합니다. 검증된 기업 언급 0개를 모두 표시하며, 보고 실적과 향후 가이던스를 분리합니다. 공개 근거는 화자가 표시된 짧은 인용문 8개로 제한됩니다. AI 분석은 불완전하거나 틀릴 수 있으므로 중요한 주장은 원문에서 확인하세요.